Ads
related to: Skyrizi- Skyrizi® Complete Sign-Up
Start Your Enrollment.
Get Access To Patient Resources.
- Preparing For Treatment
See Treatment Process Steps.
SKYRIZI® Treatment Information.
- Check Insurance Coverage
Your Insurance Questions Answered.
Connect With A Specialist Now.
- Skyrizi® Complete App
Set Medication Reminders.
Track Your Doses.
- Copay Card, If Eligible
Find Ways To Save on SKYRIZI®.
Skyrizi® Complete Savings Card.
- 1-On-1 Support Available
Nurse Ambassador Support For You.
Answers To Your Savings Questions.
- Skyrizi® Complete Sign-Up
Search results
AbbVie: An Undervalued Giant
GuruFocus.com via Yahoo Finance· 2 days agoAbbVie's resilience: Surging beyond Humira with sky-high Skyrizi and Rinvoq revenue Revenue in the fourth quarter of 2023 was $14.3 billion, representing...
Long Live the Dividend Kings: 3 Top Picks to Build an Income Portfolio
InvestorPlace· 20 hours agoWhether an investor seeks steady income or long-term growth, the dividend king stocks are a great...
‘Awful’: Internet says as ‘Teen Mom’ star Kayla Sessler reveals third baby's name on social media
MEAWW· 2 days agoLOS ANGELES, CALIFORNIA: Kayla Sessler well-known for her appearance on the reality TV show 'Teen...
AbbVie (ABBV) to Buy Landos to Strengthen Autoimmune Portfolio
Zacks via Yahoo Finance· 3 days agoThe deal will strengthen AbbVie’s inflammatory and autoimmune disease portfolio, which includes...
AbbVie to bolster immunity illness drug pipeline with Landos deal
Reuters via AOL· 4 days agoLandos is currently conducting a mid-stage study of its lead experimental drug NX-13 in a type of an...
AbbVie to buy immune drug developer Landos
BioPharma Dive via Yahoo Finance· 4 days agoAbbVie already sells two blockbuster drugs that can treat types of IBD: Rinvoq, approved for ulcerative colitis and Crohn’s, and Skyrizi, which is only...
Council Post: What's Driving Big Pharma's Recent Market Performance?
Forbes· 4 days agoThe financial performance of major pharmaceutical companies highlights the divergent trajectories of...
We Just Upgraded These 6 Companies. Is It Time to Buy the Stocks?
Morningstar· 3 days agoWhen investing, it’s important to understand a company’s competitive advantages. Morningstar...
These stocks may have trouble living up to expectations for a big earnings turnaround this year
CNBC· 3 days agoAnalysts are predicting a major bounce back in earnings for several companies in the S & P 500 this...
Gastroenterologists Slow to Adopt Eli Lilly’s Omvoh, Pfizer’s Velsipity, and Takeda’s subcutaneous...
Morningstar· 7 days agoAmong them is Eli Lilly’s Omvoh (mirikizumab), the first FDA approved IL-23 inhibitor for UC, Pfizer’s Velsipity (etrasimod), the second Sphingosine-1 phosphate (S1P) receptor-modulator, as ...
Ads
related to: Skyrizi